Cover Image

Novel therapies in platinumrefractory metastatic germ cell tumor: a case report with a focus on a PD-1 inhibitor

Kah Poh Loh, Chunkit Fung
  • Chunkit Fung
    Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, NY, United States


Testicular germ cell tumor (GCT) is the most common malignancy in young males between the ages of 15 to 35 years. Although the overall cure rate of GCTs approaches 95%, almost 25% of patients with distant metastases die from the cancer. Active investigations on novel treatment options for platinum-refractory GCTs include immunotherapies such as programdeath 1 (PD-1)/program death-ligand 1 (PD-L1) inhibitors. In this case, we report a patient with metastatic GCTs who was treated with pembrolizumab, a PD-L1 inhibitor, in a phase II study after failing several lines of chemotherapy. We highlighted the rationale for the use of PD-L1 inhibitor in this population.


Metastatic germ cell tumor; immunotherapy; pembrolizumab; PD-L1 expression

Full Text:

Submitted: 2016-09-05 18:55:32
Published: 2017-07-03 15:32:59
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2017 Kah Poh Loh, Chunkit Fung

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185